Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068695 | 1.00 | AOC3 (0.46) | AOC3SLC6A2SLC6A4ADRB3ADRB2 | |
| SCHEMBL25263679 | 0.86 | SLC6A2 (0.48) | AOC3SLC6A2SLC6A4ADRB3ADRB2 | |
| SCHEMBL31068787 | 0.86 | SLC6A2 (0.48) | AOC3SLC6A2SLC6A4ADRB3ADRB2 | |
| SCHEMBL31068777 | 0.83 | SLC6A2 (0.55) | AOC3SLC6A2SLC6A4ADRB3ADRB2 | |
| SCHEMBL25262310 | 0.83 | SLC6A2 (0.55) | AOC3SLC6A2SLC6A4ADRB3ADRB2 | |
| SCHEMBL31664244 | 0.83 | SLC6A2 (0.55) | AOC3SLC6A2SLC6A4ADRB3ADRB2 | |
| SCHEMBL25303921 | 0.83 | AOC3 (0.47) | AOC3SLC6A2SLC6A4TAAR1TSHR | |
| SCHEMBL25833347 | 0.83 | AOC3 (0.47) | AOC3SLC6A2SLC6A4ADRB3ADRB2 | |
| SCHEMBL31419982 | 0.81 | MEN1 (0.58) | AOC3SLC6A2SLC6A4ADRB3ADRB2 | |
| SCHEMBL25299430 | 0.81 | SLC6A2 (0.44) | AOC3SLC6A2SLC6A4ADRB3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2026-02-12 | — | — | US | disclosed |
| EP-4463453-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2024-11-20 | — | — | EP | disclosed |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2024-09-19 | — | — | US | disclosed |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| WO-2023135233-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | WO | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
| EP-4212531-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | AOC3 3111/4885SLC6A2 1803/4885SLC6A4 2807/4885 |
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | BRAF, RAF1, NRAS | AOC3 1889/4885SLC6A2 3736/4885SLC6A4 4506/4885 |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | AOC3 3111/4885SLC6A2 1803/4885SLC6A4 2807/4885 |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | AOC3 3111/4885SLC6A2 1803/4885SLC6A4 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.